Fabry Disease Clinical Trial
— MAP-FABOfficial title:
T1 Mapping in Diagnosis and Follow up of Fabry Disease
Fabry disease (OMIM-301500, FD) is a lysosomal storage disease with X-linked inheritance secondary to mutations in the α-galactosidase A gene (GLA), which cause absence or decreased activity of the lysosomal hydrolase a-galactosidase A (a-gal A). The accumulation of globotriaosylceramide (Gb3) leads to multiple organs dysfunction, especially in three key organs: kidney, heart and cerebrovascular system. Progressive nephropathy is one of the main features of Fabry disease and is marked by an insidious development. The investigators are facing different current challenges about treatment initiation in non-classic phenotype patients, optimal dose after treatment initiation, and treatments monitoring in Fabry nephropathy. That is even more important that the enzyme replacement therapy is expensive and a lifelong commitment. Functional magnetic resonance imaging (MRI) is now able to provide T1 mapping sequence. In Fabry disease, T1 mapping is currently used to assess the degree of myocardial involvement. The MRI for assessement of Fabry Cardiomyopathy is now recommended by the 2022 national diagnostic and care protocol (PNDS) in France. However there is no data about T1 mapping values in kidney in Fabry's disease The main Objective is to describe renal performance through multi-parametric MRI in Fabry nephropathy and the primary outcome will be the quantification of renal T1 in Fabry patients.
| Status | Recruiting |
| Enrollment | 70 |
| Est. completion date | August 7, 2025 |
| Est. primary completion date | August 7, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patient with confirmed Fabry disease Or Control patients: Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis - Adult patient - Patient informed of the study and agree to participate - Patient affiliated to a social security or beneficiaries of a similar scheme Exclusion Criteria: - Weight > 130 kg - kidney transplant, - polycystic kidney disease, - Pregnant, parturient or breastfeeding - Contraindications to MRI - Subject participating in another research including an exclusion period still in progress at inclusion - Persons deprived of their liberty by a judicial or administrative decision, - Adults subject to a legal protection measure (safeguard measure, guardianship, curators) |
| Country | Name | City | State |
|---|---|---|---|
| France | Hopital Femme Mère Enfant | Bron | |
| France | Hopital Edouard Herriot | Lyon |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | T1 value measured | Difference in the measurement of T1 mapping by MRI in Fabry disease patients compared with controls.
T1 mapping is a MRI sequence to estimate renal fibrosis |
Day 1 | |
| Secondary | Apparent diffusion coefficient (ADC) coefficient values | ADC coefficient values to measure the degree of fibrosis in Fabry nephropathy in Fabry disease patients compared with controls. | Day 1 | |
| Secondary | R2* coefficient values | R2* values to measure the degree of renal alteration in Fabry nephropathy in Fabry disease patients compared with controls. | Day 1 | |
| Secondary | T2 value measured | Comparison of T2 values measured by T2 mapping MRI between patients with Fabry disease and controls.
T2 mapping is a MRI sequence to estimate renal alteration |
Day 1 | |
| Secondary | T1 mapping measurement Fabry disease | Comparison of T1 mapping values within 3 different subgroups of patients with Fabry disease (treated men, treated or untreated women) | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between the T1 values measured and concentration of plasma globotriaosylsphingosine (LysoGb3) | Day 1 | ||
| Secondary | In Fabry disease patients, evaluation of the association between glomerular filtration rate and ADC value measured | ADC value measured by diffusion-weighted MRI | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between glomerular filtration rate and R2* value measured | R2* value measured by blood oxygen level-dependent (BOLD) MRI | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between glomerular filtration rate and T2 value measured | T2 value measured by T2 mapping MRI | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between proteinuria and ADC value measured | ADC value measured by diffusion-weighted MRI | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between proteinuria and R2* value measured | R2* value measured by BOLD MRI | Day 1 | |
| Secondary | In Fabry disease patients, evaluation of the association between proteinuria and T2 value measured | T2 value measured by T2 mapping MRI | Day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04893889 -
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.
|
N/A | |
| Completed |
NCT04455230 -
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
|
Phase 1/Phase 2 | |
| Completed |
NCT01218659 -
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
|
Phase 3 | |
| Completed |
NCT00304512 -
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
|
Phase 2 | |
| Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
| Completed |
NCT03500094 -
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
|
Phase 3 | |
| Withdrawn |
NCT04143958 -
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
|
Phase 4 | |
| Recruiting |
NCT02994303 -
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy
|
N/A | |
| Completed |
NCT01947634 -
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
|
N/A | |
| Recruiting |
NCT01695161 -
Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.
|
N/A | |
| Completed |
NCT01853852 -
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
|
Phase 1 | |
| Completed |
NCT00701415 -
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
|
Phase 3 | |
| Completed |
NCT00068107 -
Dosing Study of Replagal in Patients With Fabry Disease
|
Phase 2 | |
| Completed |
NCT01997489 -
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
|
Phase 4 | |
| Recruiting |
NCT06007768 -
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
|
||
| Recruiting |
NCT05698901 -
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
|
||
| Active, not recruiting |
NCT03305250 -
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
|
N/A | |
| Terminated |
NCT00526071 -
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
|
Phase 2 | |
| Active, not recruiting |
NCT03566017 -
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
|
Phase 3 | |
| Recruiting |
NCT06065605 -
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
|